SCHEMBL5546148

SCHEMBL5546148

O=[C]OCc1coc2cc(F)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.46
CYP11B2 P19099 3/20 0.46
CYP19A1 P11511 2/20 0.46
CYP17A1 P05093 1/20 0.46
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 2/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
PPARG P37231 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
PIM1 P11309 1/20 0.35
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536051 0.88 PTPN1 (0.43) CYP11B1CYP11B2CYP19A1CYP17A1KDM4E
SCHEMBL5540063 0.85 CYP11B1 (0.44) CYP11B1CYP11B2CYP19A1CYP17A1TSHR
SCHEMBL5543815 0.82 MAPT (0.36) CYP11B1CYP11B2TSHRSMN1; SMN2GAA
SCHEMBL5535896 0.82 MAPT (0.36) SMN1; SMN2GAAPPARDPPARAKDM4E
SCHEMBL5544390 0.81 CYP11B1 (0.41) CYP11B1CYP11B2CYP19A1CYP17A1TSHR
SCHEMBL2093954 0.74 CYP11B1 (0.49) CYP11B1CYP11B2CYP19A1CYP17A1TSHR
SCHEMBL914068 0.74 CYP11B1 (0.49) CYP11B1CYP11B2CYP19A1CYP17A1TSHR
SCHEMBL5541957 0.74 PTPN1 (0.41) CYP11B1CYP11B2CYP19A1CYP17A1KDM4E
SCHEMBL5537157 0.73 HTR1A (0.35)
SCHEMBL5536452 0.73 PTPN1 (0.43) SMN1; SMN2GAANPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP11B1 514/4885CYP11B2 373/4885CYP19A1 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.